Clinical trials: Infection, Community-Acquired
Covid19, Community-Acquired Respiratory Tract Infection
Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19
Solving the problem of detecting asymptomatic carriers who can transmit infection is key to protecting vulnerable residents of nursing homes and assisted living facilities, to protecting frontline workers who care for them, and…
- Trial name
- NCT04548895
- Testing
- Observational measurement of biometric data. No change to health care provided.
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Health Stream Analytics, LLC
Covid19
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
- Trial name
- ESsCOVID (NCT04576728)
- Testing
- Trimodulin
- Where
- 17 sites in Brazil, France and 2 more
- Volunteers
- 166 people
- Sponsor
- Biotest
Community-acquired Pneumonia
A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of intravenous nemonoxacin compared with intravenous moxifloxacin in adult patients with community-acquired pneumonia (CAP).
- Trial name
- NCT02205112
- Testing
- Nemonoxacin, Levofloxacin
- Where
- 63 sites in China, Taiwan
- Volunteers
- 598 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Community-acquired Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical…
- Trial name
- ESsCAPE (NCT05722938)
- Testing
- Trimodulin
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 590 people
- Sponsor
- Biotest
Community-Acquired Bacterial Pneumonia (CABP)
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).
- Trial name
- NCT01198626
- Testing
- JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 32 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Pneumonia
Community-Acquired Pneumonia (CAP) Surveillance
Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.
- Trial name
- NCT01416506
- Testing
- No Drug
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Bayer
Community-acquired Pneumonia
Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia
The purpose of this study is to determine the safety and efficacy of ONO-5046Na in patients with acute respiratory failure associated with community-acquired pneumonia
- Trial name
- NCT00417326
- Testing
- ONO-5046Na
- Where
- 9 sites in Japan
- Volunteers
- 174 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Community-Acquired Pneumonia (CAP)
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens.
- Trial name
- NCT00035347
- Testing
- IV azithromycin, ceftriaxone, oral azithromycin
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
In order to verify the clinical value and safety of Xiyanping injection in children with CAP, we intend to carry out this multi-center, large-sample, non-intervention clinical research through more rigorous and scientific design.
- Trial name
- NCT04158310
- Volunteers
- 9,207 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Pneumonia
Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia
Primary Objective: To evaluate the clinical efficacy of pristinamycin at a dose of 2g x 2/day for 2 days then 1g x 3/day for 5 to 7 days versus amoxicillin 1g x3 /day for 7 to 9 days, 5 to 9 days after the end of treatment.
- Trial name
- NCT02332577
- Testing
- PRISTINAMYCIN XRP7263, Amoxicillin
- Where
- 19 sites in France, Tunisia
- Volunteers
- 161 people
- Sponsor
- Sanofi
Community-acquired Infection
A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers
This is a two-part study. Part A is a three-period study in approximately 24 healthy male Japanese and Caucasian subjects. Period 1 and Period 2 will be an open label study to investigate the safety, tolerability, and…
- Trial name
- NCT01495065
- Testing
- GSK2251052 750 mg, GSK2251052 1500 mg, GSK2251052 1500 mg BID
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia
A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia
The purpose of this study is to assess if a therapy with oral and intravenous moxifloxacin is as effective as a therapy with intravenous ceftriaxone + intravenous azithromycin followed by oral amoxicilline/clavulanate and oral…
- Trial name
- NCT00717561
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin
- Where
- 23 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Bayer
Pneumonia
An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia
To validate the efficacy and safety of azithromycin for the treatment of Chinese patients hospitalized with community-acquired pneumonia (CAP), compared with cefuroxime or the combination of cefuroxime plus oral erythromycin.
- Trial name
- NCT00648726
- Testing
- cefuroxime plus erythromycin, azithromycin (Zithromax), cefuroxime
- Where
- 5 sites in China
- Volunteers
- 139 people
- Sponsor
- Pfizer
Pneumonia
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia
The purpose of this study is to compare the efficacy and safety of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
- Trial name
- NCT00336544
- Testing
- Cethromycin, Clarithromycin
- Where
- 13 sites in United States
- Volunteers
- 522 people
- Sponsor
- Advanced Life Sciences, Inc.
Pneumonia
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
- Trial name
- NCT00084071
- Testing
- Tifacogin
- Where
- 150 sites in United States, Argentina and 16 more
- Volunteers
- 2,136 people
- Sponsor
- Novartis Pharmaceuticals
Community-acquired Bacterial Pneumonia
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- SOLITAIRE-IV (NCT01968733)
- Testing
- Solithromycin, Moxifloxacin
- Where
- 270 sites in United States, Argentina and 24 more
- Volunteers
- 863 people
- Sponsor
- Melinta Therapeutics, Inc.
Community Acquired Pneumonia
Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia
A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.
- Trial name
- NCT01081964
- Testing
- Zabofloxacin, Levofloxacin 500mg, Zabofloxacin 400mg
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- IASO Pharma Inc.